The example of Ranbaxy is still fresh in memory. One of India's biggest drug manufacturers at the time, Ranbaxy pleaded guilty to felony charges and paid a $500 million fine, the largest ever levied against a generic company. It led to the exit of the promoters and the company's sale. A while back, a group of health activists, including Ranbaxy whistleblower Dinesh Thakur, petitioned the ministry of health to ensure greater transparency in regulation. Citing a Parliamentary committee report on the functioning of the CDSCO, which highlighted serious lapses in India's drug approval standards, the petition highlighted how approvals had reached a slippery slope. India has also been coming under increased scrutiny by the US Food and Drugs Administration (FDA) for safety lapses, falsified drug test results, and selling fake medicines. The World Health Organization had estimated that one in five drugs made in India was fake.